NCAM1 and sarcoidosis: The practical bearing of CD56+ T cell expansion in PB from patients with sarcoidosis is unclear.6 12 However, given their potential of producing IFN-γ9 and our observation of a decrease paralleled by clinical improvement in most patients after infliximab therapy suggest that CD56+ T cells contribute to systemic inflammation.